ANDA 207971, held by Chartwell Rx. Fingolimod Hydrochloride.
As of Nov 16, 2026, ANDA 207971 (Fingolimod Hydrochloride), held by Chartwell Rx, was first approved by FDA on Jun 29, 2020, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 29, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fingolimod HydrochlorideEQ 0.5MG BASE · capsule;oral | Fingolimod Hydrochloride | Discontinued |
| Feb 18, 2026 | Supplement 3Labeling · Standard review | Approved | None posted |
| Feb 18, 2026 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jun 29, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters